<DOC>
	<DOCNO>NCT03043794</DOCNO>
	<brief_summary>This Phase II trial preoperative stereotactic radiation breast low risk breast cancer .</brief_summary>
	<brief_title>Study Stereotactic Radiotherapy Breast Cancer</brief_title>
	<detailed_description>This single arm phase II study design , evaluate pathologic response ( primary endpoint ) well toxicity , cosmetic outcome , quality life , translational correlate ( secondary endpoint ) pre-operative stereotactic body radiotherapy ( SBRT ) intact breast tumor patient hormone-receptor positive early stage breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female sex Age &gt; = 50 year age Invasive ductal carcinoma Clinically radiographically T1 tumor Clinically node negative Clearly demarcate tumor magnetic resonance imaging ( MRI ) , determine treat physician ( MRI may do enrollment do prior ) Planning breast conserving surgery include sentinel node biopsy â‰¥10 % expression ER and/or PR HER2 use current College American Pathologists guideline Postmenopausal Willing able provide inform consent Medical condition may increase risk poor cosmetic outcome ( i.e . Lupus , rheumatoid arthritis , scleroderma Pure DCIS without invasive cancer Patients receive receive neoadjuvant systemic therapy , endocrine therapy , target agent Breast implant involve breast unless implant remove prior initiation study treatment Positive pregnancy test Subjects without placement biopsy clip diagnostic procedure unwilling undergo clip placement . Unable meet dosimetric constraint due tumor location and/or patient anatomy Planning mastectomy Unable tolerate prone positioning</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>early stage</keyword>
	<keyword>low risk</keyword>
</DOC>